Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma

Combination chemotherapy with CHOP-Pepleo regimen (cyclophosphamide, adriamycin, vincristine, prednisolone, and pepleomycin), or COP-Pepleo refimen (cyclophosphamide, vincristine, prednisolone, and pepleomycin), was used as a remission induction therapy for patients with mostly advanced non-Hodgkin's lymphomas. Among 23 patients treated with CHOP-Pepleo or CHOP without Pepleo (5 patients), 57% achieved complete remission with 78% overall response (complete remission plus partisl remission). Among 12 patients treated with COP-Pepleo, 50% achieved complete remissions with 83% overall response. No significant difference was odserved in response rates between two groups. Median follow-up durations ware 14 months for CHOP-People and 16 months for COP-Pepleo and 4 patients (67%) treated with COP-Pepleo relapsed within 20 months after achieving complete remission. Relapse-free survival rates at 4 years ware 54% for CHOP-Pepleo and 34% for COP-Pepleo. Each survival curve in the patients treated with CHOP-Pepleo or COP-Pepleo showed a plateau after 24 months. Though the addition of adriamycin did not improve complete remission rate significantly as a whole, the complete remission rate in stage Ⅳ , overall survival and relapse-free survival ware favorably inproved by the addition of adriamycin. Further study will be needed to assess the effect of adriamycin on response and survival in patients eith non-Hodgkin's lymphomas.

Non-Hodgkin's Lymphoma

Chemotherapy

CHOP-Pepleo

COP-Pepleo